The indications for heparin and LMWH are slightly different. Heparin has equal anticoagulant and antithrombotic effects, while low molecular weight heparin has stronger antithrombotic effects.
Heparins Manufacturer heparin for:
Thrombotic or embolic diseases (myocardial infarction, thrombophlebitis, pulmonary embolism, etc.) ;
Disseminated intravascular coagulation (DIC) due to various causes;
It is also used for hemodialysis, extracorporeal circulation, catheterization, microvascular surgery and so on. , and some blood samples or instruments for anticoagulant therapy.
Heparins Manufacturer low molecular weight heparin for:
Prevention of venous thromboembolic diseases, especially deep venous thrombosis after orthopedic or general surgery;
Treatment of deep vein thrombosis;
It is used for the treatment of unstable angina pectoris in acute stage of non-ST segment elevation myocardial infarction.
Prevention of blood clots in dialyzer during hemodialysis.
Heparins Manufacturer describes its side effects:
The bleeding rate of low molecular weight heparin was lower than that of heparin. Monitoring of activated partial thrombin time (APTT) is necessary when heparin is administered, especially when intravenous drip is used. Low molecular weight heparin can monitor x FACTOR A when necessary.
Protamine binds only to high molecular weight heparin. Protamine can completely eliminate the anticoagulant effect of heparin (1mg protamine sulfate can neutralize 100U heparin), and can partially eliminate the anticoagulant effect of low molecular weight heparin.
Heparin can cause thrombocytopenia, so platelet counts should be monitored. The incidence of thrombocytopenia caused by LMWH is low, but platelet counts should be monitored.
Large doses or long-term use of heparin can occasionally cause osteoporosis and spontaneous spinal fractures. Compared with heparin, low molecular weight heparin rarely causes osteoporosis.